

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**CONTENTS**

---

	Page
Reference and administrative details of the charity, its trustees and advisers	1
Trustees' report	2 - 7
Trustees' responsibilities statement	8
Independent auditor's report	9 - 11
Statement of financial activities	12
Balance sheet	13
Statement of cash flows	14
Notes to the financial statements	15 - 26

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND  
ADVISERS  
FOR THE YEAR ENDED 31 MARCH 2019**

---

<b>Trustees</b>	Dr Graham Spittle, CBE, Chair of Trustees Professor Sir Alex Markham, Chair of Audit Committee Professor Jonathan Montgomery, Chair of Nominations Committee David Zahn, Chair of Remuneration Committee Professor Sir James Smith Professor Dame Janet Thornton Professor Sarah Harper CBE (appointed 21 June 2018) Baroness Lucy Jeanne Neville-Rolfe (appointed 13 December 2018) Dr Frances Rawle (appointed 25 July 2018)
<b>Company registered number</b>	10887014
<b>Registered office</b>	Wellcome Trust Gibbs Building 215 Euston Road London NW1 2BE
<b>Principal operating office</b>	215 Euston Road London NW1 2BE
<b>Company secretary</b>	Amanda Borton
<b>Independent auditor</b>	SRLV Audit Limited Chartered Accountants and Statutory Auditor Elsley Court 20-22 Great Titchfield Street London W1W 8BE
<b>Bankers</b>	AIB (GB) Ealing Cross 85 Uxbridge Road London W5 5TH
<b>Solicitors</b>	Freshfields 65 Fleet Street London EC4Y 1HT

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

The trustees (who are also the officers of the charity for the purposes of the Companies Act) present their annual report together with the financial statements of Health Data Research UK ("HDR UK", the "company", the "charity, the "charitable company") for the year ended 31 March 2019.

The trustees are in the process of applying to the Charity Commission to obtain charitable status for the company. The trustees have prepared the annual report and financial statements on the basis that charitable status will be awarded.

The trustees confirm that the annual report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) as amended by Update Bulletin 1 (effective 1 January 2015).

### **Objectives and activities**

HDR UK is the national institute for health data science. Our mission is to unite the UK's health data to enable discoveries that improve people's lives. The UK has some of the most comprehensive data sources internationally, from NHS data, to clinical trials, world-leading cohort studies and social, molecular and environmental data. Our ambition is to revolutionise research and innovation in the UK by working in partnership to enable linkage, access and analysis of these health data at scale to facilitate better health outcomes.

Over the next 20 years, our vision is for every health and care interaction and research endeavour to be enhanced by access to large scale data and advanced analytics.

Empowering researchers with access to rich, large-scale data combined with new scientific insights will transform research and innovation and lead to better health outcomes through significant advancements in our understanding, prevention, diagnosis and treatment of disease.

To achieve this aspiration, we are bringing together the NHS, the public, industry and academia as one combined force. A collaboration of this scale has never been seen before and it will significantly transform the future of healthcare by developing and championing the best in science, people and infrastructure underpinned by earning public trust. Each of these elements has a crucial part to play in advancing healthcare improvements and will fuse together to create an unparalleled ecosystem for health data science and innovation to flourish.

We are One Institute, delivering our vision through:

#### **Science**

Through our University and NHS partners, Health Data Research UK has access to some of the UK's brightest minds in biomedical and clinical science, maths, statistics, computing, ethics and social sciences. This provides a foundation of expertise that has a track record of developing and applying cutting-edge health data science approaches to clinical, biological, genomic and other types of diverse health data. This is stimulating world-leading scientific research, clinical trials, public health and digital health insights that will forge discovery of new diseases, increase clinical trial participation, develop the best treatments, and eliminate the most devastating diseases.

#### **People**

Delivering our ambitious vision and world-leading health data science requires a community of scientists with new skills that will strengthen medical research and open up faster, smarter pathways to patient care. Our training strategy focuses on the three fields needed to create a diverse cohort of future pioneers: statistics, informatics and health science.

Our five-year ambition is to develop 10,000 health data scientists spanning all career stages, from school leaver to senior research manager and international opinion leaders. This year we have been laying the foundations to achieve this through launching a competition for master's level programmes, gathering information on health data science training activities, and creating a research fellowship.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**Infrastructure**

We are improving access to health data by creating rich, robust, reliable and scalable infrastructure. This is underpinned with a strong governance framework and clear leadership with a focus on public engagement. Our aim is to enable researchers and innovators to access data and develop valuable insights that will enhance our understanding of disease and ultimately improve people's health.

**Public Engagement**

Achieving the confidence and trust of patients and members of the public in the use of health data for research and innovation is critical to achieving our vision. It is therefore crucial to actively engage the public at an early stage to help shape our strategy, research and every stage of the innovation process. Our One Institute strategy outlines our commitment to engaging and involving patients and the public and guides our commitment to acting in their best interests and with their backing.

**One Institute**

HDR UK is a new type of institute; we're bringing together the NHS, UK Government, industry and academia, as one combined force. Team science at this scale will significantly transform the future of healthcare by enabling and championing the best in science, people and infrastructure. Each of these elements has a crucial part to play in advancing healthcare improvements and will fuse together to create an unparalleled ecosystem for health data science to flourish.

More information on HDR UK's activities is available on the website [www.hdruk.ac.uk](http://www.hdruk.ac.uk).

**Achievements and performance**

**Science**

In 2018/19 we:

- Established six research sites, comprising 22 Universities and research Institutes across the UK,
- Created a cohort of 25 Research Directors and Associate Directors
- Established our national science priorities
- Developed joint grants, including a £10 million grant proposal with the British Heart Foundation
- Played international leadership roles on use of global health data to search for cures in Alzheimer's disease
- Created strategic partnerships with the Alan Turing Institute and the Medicines Discovery Catapult
- Undertaken a baseline of data science activity using ResearchFish to enable us to track impact
- Demonstrated outcomes from existing programmes of work that HDR UK is enabling
- Monitored the breadth of research publications that show the early work and impact of HDR UK

**People**

In 2018/19 we:

- Created an initial cohort of 180 Principal Investigators and Co-Investigators to deliver the research
- Established a Fellowship programme for health data science, recruiting 46 non-clinical HDR UK/ Rutherford Fellows, supported through funding from UK Research and Innovation
- Announced a partnership with the National Institute for Health Research Academy to jointly provide an innovative training environment for researchers working in health data science
- Launched a call for degree-awarding institutions to lead master's-level programmes in health data science
- Established a partnership with the Software Sustainability Institute to develop a core curriculum for short, continuing professional development courses in health data science and build training capacity across HDR UK and our partners

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**Infrastructure**

In 2018/19 we:

- Developed the £37.5m Digital Innovation Hub Programme after being commissioned by UK Research and Innovation to deliver this UK-wide initiative to link up the UK's health data as part of the Industrial Strategy Challenge Fund
- Created and launched the UK Health Data Research Alliance to unite expertise to establish best practice in the stewardship of the UK's health data and enable faster, more efficient access for research at scale
- Funded 10 innovative Sprint Exemplar Projects to show how technology and data solutions can improve lives and speed up innovation in the NHS and UK life sciences.
- Organised and ran a series of conferences, events and workshops to engage and involve colleagues across industry, academia, healthcare, charities, patients and the public in co-designing the specification for the Digital Innovation Hub Programme
- Established the requirements of data users and patients and used this to describe a model for how data could be linked, accessed and used safely and securely

**Public engagement**

In 2018/19 we:

- Created a Public Advisory Board through a rigorous and competitive recruitment process, resulting in nine members selected from a variety of backgrounds and perspectives
- Held our first event for patients, members of the public and charity representatives to seek input and test ideas on how to embed the public voice into the Digital Innovation Hub Programme, which has informed the criteria expected of organisations wishing to create Hubs
- Worked in partnership with colleagues in the NHS, Genomics England, Understanding Patient Data, the National Data Guardian and the Association of Medical Research Charities to increase our reach to patients and communities and to consider common principles for engaging patients in health data initiatives
- Launched new communications tools, including a website, monthly newsletter and a weekly blog, to provide a means for sharing information on how and why data is used in research.

More information on HDR UK's achievements during 2018/19 can be found in the Annual Review, available at <https://www.hdruk.ac.uk/annual-review-2019/>.

**Plans for future periods**

As the national institute for health data science, we are bringing together the sharpest scientific minds and providing safe and secure access to rich health data to better understand diseases and discover new ways to prevent, treat and cure them.

Our 'One Institute' strategy sets out our vision for the next 20 years – for large scale data and advanced analytics to benefit every patient interaction, clinical trial, biomedical discovery and enhance public health – our five year ambitions and plans for 2019/20.

It focuses on key areas of science, people and infrastructure, all underpinned by our commitment to earning public trust through engagement and involvement in the use of health data for research.

**Science**

Great science will be achieved through developing advanced techniques to analyse complex and diverse health data and seize its power to solve health challenges. By bringing together the areas of maths, statistics, computer science and interdisciplinary teams we will develop analytical methods and tools to shape the future of healthcare.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**People**

Our talent and training work aims to create a Health Data Research UK Alumnus Network of more than 10,000 health data scientists spanning all career stages, from school-leaver to senior research manager and international opinion leaders. Through programmes including masters degrees, doctoral training and fellowships, we will support both educational and career pathways in order to create leaders within health data research, to influence the science and infrastructure of tomorrow.

**Infrastructure**

With the competition for Digital Innovation Hubs opening on 7 May 2019, our commitment to great infrastructure is already underway. With an ambition to create world-leading Hubs for scientific research and digital innovation by developing a cutting-edge infrastructure and a UK approach to secure research data services, we will eliminate the restrictions to responsible health data access.

**Public involvement, engagement and participation** shapes everything we do and we are committed to earning trust in how health data is used. Health Data Research UK works in partnership with a wide range of organisations and individuals and champions the trustworthy use of data and digitisation for the public good.

More information on HDR UK's future plans is available in the strategy section of the website <https://www.hdr.uk/about/strategy/>.

**Financial review**

**Funding**

Our founding funders have jointly invested in Health Data Research UK: the Medical Research Council (MRC); the health research departments of England, Scotland, Wales and Northern Ireland (National Institute for Health Research (NIHR), Chief Scientist Office (CSO), Health and Care Research Wales, HSC Research and Development respectively), the Economic and Social Research Council (ESRC), the Engineering and Physical Sciences Research Council (EPSRC), Wellcome, and The British Heart Foundation ("Core Funders").

During 2018/19 the Core Funders agreed in principle to provide £52.7m funding to HDR UK in the 5 years to March 2023. Total funding income of £2.4m was received during the year. £2.9m of core funds are included in income in advance on the balance sheet.

An additional £5.9m restricted funding was received during the year. £5.1m capital funding was received directly from the MRC and £693k was received from UK Research and Innovation's Industrial Strategy Challenge Fund in support of the Digital Innovation Hub Programme.

Other charitable expenditure is funded by other funders, or through cost sharing with HDR UK's collaborative partners.

**Grants**

HDR UK provides long-term awards to research organisations with a track record of excellence in health data science. This is creating a national collaborative research community.

During 2018/19 HDR UK entered into agreements in principle to provide £26.6m funding in the 5 years to March 2023 to the six founding HDR UK sites: HDR UK Cambridge, HDR UK London, HDR UK Midlands, HDR UK Oxford, HDR UK Scotland and HDR UK Wales & Northern Ireland. In 2018/19 HDR UK funded £1.2m site expenditure. A further £4.9m capital grants were awarded the HDR UK sites.



**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**Reserves policy**

The Core Funders are committed to funding costs incurred by the Institute, with regular funding throughout each financial year in advance of expenditure. By the nature of this model, there is no need for significant reserves. As at 31 March 2019 total unrestricted reserves were £82,229 and total restricted reserves were £nil.

**Structure, governance and management**

HDR UK is registered as a Company limited by guarantee, set up in July 2017. The Board of Trustees is responsible for determining the overall strategy of HDR UK and govern the Company in accordance with its Memorandum and Articles of Association. The Trustees have referred to the guidance contained on the Charity Commission's general guidance on public benefit and consider HDR UK to be a public benefit entity.

The Trustees make Trustee appointments on such terms as they decide (including, without limitation, the term of his or her appointment) and review each appointment at last every three years on a rotational basis. All Trustees give of their time freely, with the Chair receiving a remuneration which was paid during the year. Details of Trustee expenses and related party transactions are disclosed in note 22 to the accounts.

In accordance with the Institute's policy, Trustees are required to disclose all relevant interests and register them with the Chair of Trustees and to withdraw from decisions where a conflict of interest arises.

New Trustees are appointed through a public appointment process, depending on the experience and key skills needed. New Trustees are recommended by the Nominations Committee and are formally appointed at an HDR UK Board meeting.

On appointment, new Trustees follow a formal induction programme, which includes initial meetings with the Chair and the Director and the provision of key governance documentation. Ongoing training is provided for Trustees as relevant throughout their term.

Day to day management of HDR UK is delegated to the Director, Professor Andrew Morris, who is supported by an executive and senior management team. The pay of the Institute's key management personnel is reviewed annually by the Remuneration Committee. The remuneration is bench-marked with organisations of a similar size and activity to ensure that the remuneration set is fair and not out of line with that generally paid for similar roles.

**Risk management**

HDR UK's vision and strategy are ambitious, and there are risks to successfully achieving HDR UK's ambition. Risk management is the responsibility of all members of HDR UK's community and is embedded into the annual strategy planning process. Risks identified are recorded in the risk register which is part of the annual strategy document and reviewed and updated through the year. Our risk management includes:

- Embedding a continuous improvement and learning culture that ensure we learn from the small incidents and 'near misses' to reduce the likelihood and severity of large-scale incidents;
- Identifying key risks to our strategy, evaluating their potential impact and assessing their likelihood;
- Evaluating the effectiveness of relevant mitigating controls;
- Agreeing, implementing and monitoring controls and actions to mitigate risks

These risk management processes are part of our ISO9001 certified quality management system. The Board, the Audit and Risk Committee, and executive and senior management support this through regular review of the risk register.

**Small Companies Exemption**

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.



**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2019**


---

**Disclosure of information to auditor**

Each of the persons who are trustees at the time when this trustees' report is approved has confirmed that:

- so far as that trustee is aware, there is no relevant audit information of which the charitable company's auditor is unaware, and
- that trustee has taken all the steps that ought to have been taken as a trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This report was approved by the trustees, on 19/12/2019 and signed on their behalf by:



**Professor Sir Alex Markham**  
Trustee

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**  
**TRUSTEES' RESPONSIBILITIES STATEMENT**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

The trustees (who are also directors of Health Data Research UK for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF HEALTH DATA RESEARCH UK**

---

**Opinion**

We have audited the financial statements of Health Data Research UK (the 'charitable company') for the year ended 31 March 2019 which comprise the statement of financial activities incorporating income and expenditure account, the balance sheet, the statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2019 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF HEALTH DATA RESEARCH UK**

---

**Opinion on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report including the strategic report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report and the strategic report have been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' report.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF HEALTH DATA RESEARCH UK**

---

**Use of our report**

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Handwritten signature in black ink that reads "SRLV Audit Limited".

Richard Gilbert (Senior Statutory Auditor)  
for and on behalf of  
**SRLV Audit Limited**

Chartered Accountants and Statutory Auditor  
Elsley Court  
20-22 Great Titchfield Street  
London  
W1W 8BE

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE  
ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2019**

		<b>Unrestricted funds 2019 £</b>	<b>Restricted funds 2019 £</b>	<b>Total funds 2019 £</b>	<b>Total funds 2018 £</b>
	<b>Note</b>				
<b>Income from:</b>					
Donations	2	<b>2,424,926</b>	<b>5,750,868</b>	<b>8,175,794</b>	403,081
Investments	3	<b>3,136</b>	-	<b>3,136</b>	81
Other income		<b>37,235</b>	-	<b>37,235</b>	-
<b>Total income</b>		<b>2,465,297</b>	<b>5,750,868</b>	<b>8,216,165</b>	403,162
<b>Expenditure on:</b>					
Governance costs	4	<b>31,434</b>	-	<b>31,434</b>	24,820
Grants, charitable activities & support costs	5,6,7	<b>2,386,790</b>	<b>5,687,053</b>	<b>8,073,843</b>	407,001
<b>Total expenditure</b>	8	<b>2,418,224</b>	<b>5,687,053</b>	<b>8,105,277</b>	431,821
<b>Net income / (expenditure) before transfers</b>		<b>47,073</b>	<b>63,815</b>	<b>110,888</b>	(28,659)
Transfers between Funds	17	<b>63,815</b>	<b>(63,815)</b>	-	-
<b>Net income / (expenditure) before other recognised gains and losses</b>		<b>110,888</b>	-	<b>110,888</b>	(28,659)
<b>Net movement in funds</b>		<b>110,888</b>	-	<b>110,888</b>	(28,659)
<b>Reconciliation of funds:</b>					
Total funds brought forward		<b>(28,659)</b>	-	<b>(28,659)</b>	-
<b>Total funds carried forward</b>		<b>82,229</b>	-	<b>82,229</b>	(28,659)

The notes on pages 15 to 26 form part of these financial statements.


**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**  
**REGISTERED NUMBER: 10887014**

**BALANCE SHEET**  
**AS AT 31 MARCH 2019**

	Note	£	2019 £	£	2018 £
<b>Fixed assets</b>					
Intangible assets	12		<b>60,796</b>		-
Tangible assets	13		<b>18,018</b>		-
			<b>78,814</b>		-
<b>Current assets</b>					
Debtors	14	<b>845,481</b>		4,676	
Cash at bank and in hand		<b>7,356,288</b>		113,346	
		<b>8,201,769</b>		118,022	
<b>Creditors:</b> amounts falling due within one year	15	<b>(8,198,354)</b>		(146,681)	
<b>Net current assets/(liabilities)</b>			<b>3,415</b>		(28,659)
<b>Net assets/(liabilities)</b>			<b>82,229</b>		(28,659)
<b>Charity funds</b>					
Unrestricted funds	17		<b>82,229</b>		(28,659)
<b>Total funds/(deficit)</b>			<b>82,229</b>		(28,659)

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the trustees on 19/12/2019 and signed on their behalf, by:



**Professor Sir Alex Markham**  
Trustee

The notes on pages 15 to 26 form part of these financial statements.



**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

	Note	2019 £	2018 £
<b>Cash flows from operating activities</b>			
Net cash provided by operating activities	19	<b>7,370,998</b>	113,346
<b>Cash flows from investing activities:</b>			
Dividends, interest and rents from investments		<b>3,136</b>	-
Purchase of tangible fixed assets		<b>(131,192)</b>	-
<b>Net cash used in investing activities</b>		<b>(128,056)</b>	-
<b>Change in cash and cash equivalents in the year</b>		<b>7,242,942</b>	113,346
Cash and cash equivalents brought forward		<b>113,346</b>	-
<b>Cash and cash equivalents carried forward</b>	20	<b>7,356,288</b>	113,346

The notes on pages 15 to 26 form part of these financial statements.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**1. Accounting policies**

**1.1 General information**

The principal objective of the charity is for the provision of grants in the medical research community.

Health Data Research UK is a private company limited by guarantee and is registered in England and Wales. The registered office and the address of the principal place of business is Wellcome Trust, Gibbs Building, 215 Euston Road, London, NW1 2BE.

**1.2 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements have been prepared to give a 'true and fair' view and have been adapted from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published on 16 July 2014 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Health Data Research UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

**1.3 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**1. Accounting policies (continued)**

**1.4 Income**

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the company of the item is probable and that economic benefit can be measured reliably.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the company which is the amount the company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

**1.5 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. HDR UK has one type of activity.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Charitable activities and governance costs are costs incurred on the company's operations, including support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

**1.6 Going concern**

The trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**1. Accounting policies (continued)**

**1.7 Intangible fixed assets and amortisation**

Intangible assets costing £1,000 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably. Intangible assets are initially recognised at cost and are subsequently measured at cost net of amortisation and any provision for impairment. Costs relating to assets developed internally are capitalised in accordance with the requirements of FRS 102.

Amortisation is provided on intangible fixed assets at rates calculated to write off the cost of each asset, less their estimated residual value, over their expected useful lives on the following bases:

Purchased software licenses	-	The contractual period
Developed software	-	Straight line over 3-5 years
Websites	-	Straight line over 3-5 years

A full year of amortisation is charged in the year when the asset is ready for use and no amortisation is charged in the year of disposal.

**1.8 Tangible fixed assets and depreciation**

All assets costing more than £1,000 are capitalised.

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the statement of financial activities incorporating income and expenditure account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Short-term leasehold improvements	-	Leasehold period
Office equipment	-	5 years
Computer equipment	-	5 years

A full year of amortisation is charged in the year when the asset is ready for use and no amortisation is charged in the year of disposal.

**1.9 Operating leases**

Rentals under operating leases are charged to the statement of financial activities incorporating income and expenditure account on a straight line basis over the lease term.

**1.10 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the bank.

**1.11 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**HEALTH DATA RESEARCH UK**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2019**

**1. Accounting policies (continued)**

**1.12 Cash at bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.13 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**1.14 Financial instruments**

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**1.15 Restatement of comparatives**

The allocation of costs between governance and charitable activities in the prior year has been restated to reflect a more appropriate classification of costs, in line with that used in the current period. £17,662 has been allocated from charitable activities to governance. The Trustees do not consider this change to have a material impact and there is no change to fund balances.

**2. Income from donations**

	<b>Unrestricted funds 2019 £</b>	<b>Restricted funds 2019 £</b>	<b>Total funds 2019 £</b>	<b>Total funds 2018 £</b>
Grants	<b>2,424,926</b>	<b>5,750,868</b>	<b>8,175,794</b>	403,081

**3. Investment income**

	<b>Unrestricted funds 2019 £</b>	<b>Restricted funds 2019 £</b>	<b>Total funds 2019 £</b>	<b>Total funds 2018 £</b>
Bank interest received	<b>3,136</b>	<b>-</b>	<b>3,136</b>	81

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

**4. Governance costs**

	Unrestricted funds	Restricted funds	Total funds 2019	Total funds 2018
	£	£	£	£
Chair remuneration	16,430	-	16,430	16,430
Audit and non-audit services	10,670	-	10,670	7,158
Board meeting costs	1,997	-	3,459	-
Reimbursement of Trustees expenses	2,337	-	875	1,232
	<b>31,434</b>	<b>-</b>	<b>31,434</b>	<b>24,820</b>

**5. Grants**

	Total 2019 £	Total 2018 £
Wellcome Sanger Institute (Genome Research Limited)	145,779	-
University College London	1,380,180	-
University of Birmingham	422,152	-
University of Oxford	1,595,617	-
The University of Edinburgh	658,279	-
Swansea University	1,894,746	-
	<b>6,096,753</b>	<b>-</b>

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

**6. Charitable activities**

	<b>Total 2019 £</b>	<b>Total 2018 £</b>
Site visits	<b>5,340</b>	5,738
Hotels, travel and subsistence	<b>67,570</b>	23,727
Meetings and events	<b>103,745</b>	434
Computer expenses	<b>4,333</b>	8,218
Printing and stationery	<b>6,014</b>	1,281
Insurances	<b>1,488</b>	525
Telephone and fax	<b>1,801</b>	90
Subscriptions	<b>2,658</b>	5,777
Bank charges	<b>801</b>	231
Staff welfare	<b>1,487</b>	28
Consultancy	<b>177,622</b>	-
Wages and salaries	<b>1,154,344</b>	271,228
National insurance	<b>63,413</b>	-
Pension cost	<b>47,323</b>	1,493
Depreciation and amortisation	<b>52,378</b>	-
	<b>1,690,317</b>	318,770



**HEALTH DATA RESEARCH UK**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2019**

**7. Support costs**

	<b>Total 2019 £</b>	Total 2018 £
Consultancy	-	63,156
Rent	<b>51,413</b>	19,591
Service charge	<b>14,713</b>	1,970
Advertising and promotion	<b>21,885</b>	3,514
HR and recruitment	<b>146,595</b>	-
Legal fees	<b>52,167</b>	-
	<b>286,773</b>	88,231

**8. Analysis of expenditure by expenditure type**

	<b>Staff costs 2019 £</b>	<b>Depreciation 2019 £</b>	<b>Other costs 2019 £</b>	<b>Total 2019 £</b>	Total 2018 £
Expenditure on grants to institutions, charitable activities and support costs	<b>1,265,080</b>	<b>52,378</b>	<b>6,756,385</b>	<b>8,073,843</b>	407,001
Expenditure on governance	<b>16,430</b>	-	<b>15,004</b>	<b>31,434</b>	24,820
	<b>1,281,510</b>	<b>52,378</b>	<b>6,771,389</b>	<b>8,105,277</b>	431,821
Total 2018	289,151	-	142,670	431,821	

Included within expenditure on grants to institutions, charitable activities and support costs is the sum of £1,170,847 (2018 - £NIL) being the cost of providing unrestricted grants to third parties and £4,925,905 (2018 - £NIL) being the cost of providing restricted grants to third parties.

**9. Net income/(expenditure)**

This is stated after charging:

	<b>2019 £</b>	2018 £
Depreciation of tangible fixed assets:		
- owned by the charity	<b>25,324</b>	-
Amortisation of intangible fixed assets	<b>27,054</b>	-
Auditor's remuneration - audit	<b>8,400</b>	5,500
Auditors' remuneration - non-audit fees	<b>2,270</b>	1,500

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

**10. Staff costs**

Staff costs were as follows:

	<b>2019</b>	2018
	<b>£</b>	<b>£</b>
Wages and salaries	<b>682,528</b>	20,439
Social security costs	<b>63,413</b>	-
Other pension costs	<b>47,323</b>	1,493
	<b>793,264</b>	21,932

Not included in staff costs were recharged seconded salary costs amounting to £471,816 (2018 - £250,789).

Including costs incurred from recharged salary costs charged by third parties, the total compensation of key management personnel was £376,581 (2018 - £176,475).

The average number of persons employed by the company during the year was as follows:

<b>2019</b>	2018
<b>No.</b>	<b>No.</b>
<b>8</b>	<b>0</b>

The number of members of staff whose emoluments, including benefits in kind, amounted to over £60,000 were as follows:

	<b>2019</b>	2018
	<b>No.</b>	<b>No.</b>
£60,001 - £70,000	<b>2</b>	-
£70,001 - £80,000	<b>-</b>	-
£80,001 - £90,000	<b>2</b>	-

In addition to the salaries and wages costs, a further £33,630 staff costs were capitalised in the year (2018:£nil).

During the year, Dr Graham Spittle, a trustee, received remuneration for his services as Chair of Trustees of £16,430 (2018 - £16,430) (see note 4). During the period, no trustee received any benefits in kind.

**11. Taxation**

**Factors affecting tax charge for the year/period**

Health Data Research UK is considered to pass the tests set out in paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the company is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 part 11 Corporation Tax Act 2010 or Section 256 of the Taxation of Charitable Gains act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

**HEALTH DATA RESEARCH UK**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2019**

**12. Intangible fixed assets**

	Total intangibles £
<b>Cost</b>	
At 1 April 2018	-
Additions	87,850
At 31 March 2019	87,850
<b>Amortisation</b>	
At 1 April 2018	-
Charge for the year	27,054
At 31 March 2019	27,054
<b>Carrying amount</b>	
At 31 March 2019	60,796
At 31 March 2018	-

**13. Tangible fixed assets**

	Short-term leasehold improvements £	Office equipment £	Computer equipment £	Total £
<b>Cost</b>				
At 1 April 2018	-	-	-	-
Additions	20,820	7,546	14,976	43,342
At 31 March 2019	20,820	7,546	14,976	43,342
<b>Depreciation</b>				
At 1 April 2018	-	-	-	-
Charge for the year	20,820	1,509	2,995	25,324
At 31 March 2019	20,820	1,509	2,995	25,324
<b>Net book value</b>				
At 31 March 2019	-	6,037	11,981	18,018
At 31 March 2018	-	-	-	-

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

**14. Debtors**

	<b>2019</b>	2018
	<b>£</b>	<b>£</b>
Trade debtors	<b>574,740</b>	-
Other debtors	<b>1,846</b>	-
Prepayments and accrued income	<b>268,895</b>	4,676
	<b>845,481</b>	4,676

**15. Creditors: Amounts falling due within one year**

	<b>2019</b>	2018
	<b>£</b>	<b>£</b>
Trade creditors	<b>600,513</b>	13,968
Other taxation and social security	-	2,431
Other creditors	<b>34,947</b>	9,233
Accruals and deferred income (see below)	<b>7,562,894</b>	121,049
	<b>8,198,354</b>	146,681

	<b>£</b>
<b>Deferred income</b>	
Deferred income at 1 April 2018	<b>40,033</b>
Resources deferred during the year	<b>2,934,273</b>
Amounts released from previous years	<b>(40,033)</b>
Deferred income at 31 March 2019	<b>2,934,273</b>

During the year, income of £2,934,273 (2018 - £40,033) was deferred as amounts received were not utilised in the period.

**16. Financial instruments**

	<b>2019</b>	2018
	<b>£</b>	<b>£</b>
Financial assets measured at fair value through income and expenditure	<b>7,356,288</b>	113,346
Financial assets measured at amortised cost	<b>576,586</b>	-
	<b>7,932,874</b>	113,346
Financial liabilities measured at amortised cost	<b>(5,264,081)</b>	(104,217)

Financial assets measured at fair value through income and expenditure comprise cash at bank and in hand.

Financial assets measured at amortised cost comprise trade debtors and other debtors.

Financial liabilities measured at amortised cost comprise trade creditors, other taxation and social security, other creditors and accruals.

**HEALTH DATA RESEARCH UK**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2019**

**17. Statement of funds**

**Statement of funds - current year**

	Balance at 1 April 2018 £	Income £	Expenditure £	Transfers between funds £	Balance at 31 March 2019 £
<b>Unrestricted funds</b>					
General funds - all funds	(28,659)	2,465,297	(2,418,224)	63,815	82,229
Restricted funds - all funds	-	5,750,868	(5,687,053)	(63,815)	-
<b>Total of funds</b>	<b>(28,659)</b>	<b>8,216,165</b>	<b>(8,105,277)</b>	<b>-</b>	<b>82,229</b>

**Statement of funds - prior year**

	Balance at 27 July 2017 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2018 £
<b>Unrestricted funds</b>					
General funds - all funds	-	403,162	(431,821)	-	(28,659)

Transfers between funds are fixed asset transfers of £78,815 and £15,000 designation of unrestricted funds.

**18. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	Unrestricted funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Intangible fixed assets	60,796	-	60,796
Tangible fixed assets	18,018	-	18,018
Current assets	4,270,921	3,930,848	8,201,769
Creditors due within one year	(4,267,506)	(3,930,848)	(8,198,354)
	<b>82,229</b>	<b>-</b>	<b>82,229</b>

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

**18. Analysis of net assets between funds (continued)**

**Analysis of net assets between funds - prior year**

	Unrestricted funds 2018 £	Restricted funds 2018 £	Total funds 2018 £
Current assets	118,022	-	118,022
Creditors due within one year	(146,681)	-	(146,681)
	<u>(28,659)</u>	<u>-</u>	<u>(28,659)</u>

**19. Reconciliation of net movement in funds to net cash flow from operating activities**

	<b>2019</b> £	2018 £
Net income/(expenditure) for the year (as per Statement of Financial Activities)	<b>110,888</b>	(28,659)
<b>Adjustment for:</b>		
Depreciation and amortisation charges	<b>52,378</b>	-
Net bank interest	<b>(3,136)</b>	-
Increase in debtors	<b>(840,805)</b>	(4,676)
Increase in creditors	<b>8,051,673</b>	146,681
<b>Net cash provided by operating activities</b>	<b><u>7,370,998</u></b>	<u>113,346</u>

**20. Analysis of cash and cash equivalents**

	<b>2019</b> £	2018 £
Cash at bank and in hand	<b>7,356,288</b>	113,346
Total	<b><u>7,356,288</u></b>	<u>113,346</u>

**21. Operating lease commitments**

At 31 March 2019 the total of the charitable company's future minimum lease payments under non-cancellable operating leases was:

	<b>2019</b> £	2018 £
<b>Amounts payable:</b>		
Within 1 year	<b><u>14,396</u></b>	<u>27,567</u>

**HEALTH DATA RESEARCH UK**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2019**

---

**22. Related party transactions**

During the year, the company received grants of £7,457,477 (2018 - £403,081) from The Medical Research Council. The Medical Research Council is a founding member of the charitable company.

During the year, the company awarded grants totaling £145,779 (2018 - £NIL) to Genome Research Limited. Professor Sir James Smith, a trustee, is a director of Genome Research Limited.

During the year, Dr Graham Spittle, CBE, a trustee, was paid £16,430 (2018 - £16,430) for his services as Chair of Trustees. At the year end there was £NIL (2018 - £NIL) owed to the trustee.

During the year, trustees were reimbursed expenses amounting to £2,337 (2018 - £1,232). The nature of the expenses were travel and subsistence.